论文部分内容阅读
三阴性乳腺癌（ TNBC）是乳腺癌的一种临床亚型，具有独特的病理特点和分子生物学特性。由于此类型乳腺癌对放疗、化疗、内分泌治疗效果欠佳，表现为复发早、进展快、生存期短和预后较其他类型乳腺癌差，导致TNBC的治疗成为世界性的难题。近年来，研究者们对TNBC的分子靶向治疗进行了一系列探索，TNBC特殊靶点的发现以及靶向药物的发展，为TNBC的临床治疗带来了新的突破。分子靶向药物或化疗联合分子靶向药物治疗比常规标准治疗效果更好，临床获益更大。“,”Triple negative breast cancer(TNBC) is a clinical subtype of breast cancer,with unique path-ologic characteristics and molecular biological characteristics.Due to the poor effect of radiotherapy,chemo-therapy and endocrine therapy for the disease,characterized by early recurrence,fast progression,short life-time and worse prognosis than the other types of breast cancer,the treatment for TNBC has become a world-wide problem.In recent years,the researchers have implemented a series of exploration on the targeted thera-py for TNBC,and the discovery of specific targets of TNBC and the development of targeted drugs has brought new breakthrough to the clinical treatment for TNBC .Several clinical trials have confirmed that the molecular targeted drugs or chemotherapy combined with molecular targeted drug treatment have better effects than con-ventional standard treatment, and with better clinical benefit.